Sera Prognostics Revenue and Competitors

Millcreek, UT USA

Location

$250.3M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Sera Prognostics's estimated annual revenue is currently $20.3M per year.(i)
  • Sera Prognostics's estimated revenue per employee is $263,701
  • Sera Prognostics's total funding is $250.3M.

Employee Data

  • Sera Prognostics has 77 Employees.(i)
  • Sera Prognostics grew their employee count by -9% last year.

Sera Prognostics's People

NameTitleEmail/Phone
1
VP – Quality | RegulatoryReveal Email/Phone
2
VP, Commercial Operations, Analytics, and BillingReveal Email/Phone
3
General CounselReveal Email/Phone
4
VP CommercializationReveal Email/Phone
5
VP, Corporate ControllerReveal Email/Phone
6
VP, Clinical OperationsReveal Email/Phone
7
ControllerReveal Email/Phone
8
VP Clinical SciencesReveal Email/Phone
9
VP Quality/RegulatoryReveal Email/Phone
10
Chief Scientific OfficerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.8M5-17%N/AN/A
#2
$1.4M9-10%N/AN/A
#3
$5.9M3841%N/AN/A
#4
$1.1M7-53%N/AN/A
#5
$1.6M1011%N/AN/A
#6
$21.2M13710%N/AN/A
#7
$1.6M33-48%$17.8MN/A
#8
$1.9M120%N/AN/A
#9
$3.7M249%N/AN/A
#10
$0.9M60%N/AN/A
Add Company

What Is Sera Prognostics?

In collaboration with the National Institutes of Health Maternal Fetal Medicine Network, Sera's scientific cofounders, Steven W. Graves, Ph.D., a professor in the department of Chemistry and Biochemistry at Brigham Young University and M. Sean Esplin, M.D., an associate professor and high-risk obstetrician at the University of Utah School of Medicine, identified biomarkers detectable from simple blood tests that can help predict the likelihood of preterm delivery and other pregnancy complications. Sera Prognostics has exclusively licensed rights to the preterm birth and preeclampsia biomarkers and the proteomics discovery technology for use in developing diagnostics to help predict and manage pregnancy complications.

keywords:N/A

$250.3M

Total Funding

77

Number of Employees

$20.3M

Revenue (est)

-9%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Sera Prognostics News

2022-04-13 - SERA PROGNOSTICS ANNOUNCES THE APPOINTMENT ...

JANE F. BARLOW TO THE SERA PROGNOSTICS BOARD. Published: Apr 12, 2022. - Accomplished business and health services leader joins Sera in its quest to improve...

2022-03-30 - Sera Prognostics, Inc. (SERA) Q4 2021 Earnings Call Transcript

Good afternoon and welcome to the Sera Prognostics' conference call to review fourth quarter and fiscal year of 2021 results.

2022-03-30 - SERA PROGNOSTICS REPORTS FOURTH QUARTER 2021 ...

Sera Prognostics is a leading health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care.

2021-09-28 - Sera Prognostics : Appoints Dr. Paul Kearney as Chief Data Officer

Brings extensive data science, bioinformatics and proteomics experience to foster further product innovation and informed healthcare insights into pregnancy SALT LAKE CITY, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Sera Prognostics Inc., The Pregnancy Company™ (NASDAQ: SERA), focused on improving mate ...

2021-09-20 - Sera Prognostics to be Added to Russell 2000 Index

SALT LAKE CITY, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Sera Prognostics Inc., The Pregnancy Company™ (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that according to a preliminary list ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$20.8M9910%N/A
#2
$54M1523%N/A
#3
$40.9M2486%N/A
#4
$102.8M344-1%N/A
#5
$175.9M62010%N/A